Shares of Canfor Co. (TSE:CFP – Get Free Report) have been assigned an average recommendation of “Buy” from the six brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating, three have assigned a buy rating and two have issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is C$21.33.
A number of equities research analysts have recently weighed in on CFP shares. Scotiabank reduced their price target on shares of Canfor from C$20.00 to C$19.00 and set a “sector perform” rating on the stock in a research note on Tuesday, July 30th. TD Securities cut their target price on shares of Canfor from C$22.00 to C$21.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th. CIBC lifted their target price on shares of Canfor from C$20.00 to C$21.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 29th. Royal Bank of Canada lifted their target price on shares of Canfor from C$18.00 to C$19.00 and gave the stock an “outperform” rating in a research report on Monday, July 29th. Finally, BMO Capital Markets cut their target price on shares of Canfor from C$22.00 to C$20.00 and set a “strong-buy” rating on the stock in a research report on Tuesday, July 23rd.
Get Our Latest Stock Analysis on Canfor
Canfor Trading Down 0.4 %
About Canfor
Canfor Corporation operates as an integrated forest products company in the United States, Asia, Canada, Europe, and internationally. It operates in two segments, Lumber, and Pulp and Paper. The company manufactures and sells softwood lumber, remanufactured lumber products, engineered wood, and other lumber-related products, as well as wood chips and pellets; and generates green energy.
Read More
- Five stocks we like better than Canfor
- Learn Technical Analysis Skills to Master the Stock Market
- Intel: Is Now the Time to Be Brave?Â
- 3 Tickers Leading a Meme Stock Revival
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Business Services Stocks Investing
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Canfor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Canfor and related companies with MarketBeat.com's FREE daily email newsletter.